RADIOIODINE-RESISTANT DIFFERENTIATED THYROID CANCER: CLINICOPATHOLOGICAL CHARACTERISTICS, MOLECULAR GENETIC ALTERATIONS. REVIEW.
....1530/ERC-15-0300. Epub 2015 Aug 25. PMID: 26307020. 74. Van Nostrand D. The benefits and risks of I-131 therapy in patients with well-differentiated thyroid cancer. Thyroid. 2009 Dec;19(12):1381-91. doi: 10.1089/thy.2009.1611. PMID: 20001720. 75. Vasil'ev ... ... Dec 16. PMID: 26675742; PMCID: PMC4709201. 80. Xing M., Liu R., Liu X., Murugan A.K., Zhu G., Zeiger M.A., Pai S., Bishop J. BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence....
Изменен: 28.04.2024Путь: Главная / Home / Publications
RADIOIODINE-RESISTANT DIFFERENTIATED THYROID CANCER: CLINICOPATHOLOGICAL CHARACTERISTICS, MOLECULAR GENETIC ALTERATIONS. REVIEW.
2 2024
Изменен: 28.04.2024Путь: Главная / Публикации
Результаты поиска 1 2 из 2
Начало | Пред. | 1 | След. | Конец
Отсортировано по релевантности | Сортировать по дате